NDA 200063 · Azurity
Contrave
Bupropion Hydrochloride, Naltrexone Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 10, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
440
96 Phase 3, 24 recruiting
FAERS reports
8,503
2,837 serious, 30 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) CONTRAVE is not approved for use in pediatric patients. ( 5.1 ) SUICIDALITY AND ANTIDEPRESSANT DRUGS CONTRAVE ® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents,...
What it is approved for
From the label in effect Nov 10, 2025.
CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CONTRAVE is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. ( 1 ) Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated. ( 1 , 4 ) Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. CONTRAVE contains naltrexone and bupropion. Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated.
Mechanism: CONTRAVE has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 10, 2014 Original approval · Type 4 - New Combination LabelReviewSummary Review
1 products under this application
- CONTRAVE · BUPROPION HYDROCHLORIDE 90MG; NALTREXONE HYDROCHLORIDE 8MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.
- Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)Pivotal-lookingTerminated
Orexigen Therapeutics, IncIndustry
NCT01601704 · 8,910 participants · Start Jun 2012 · Primary completion Aug 2015
Drug: NB32; PBO · For: Obesity; Overweight
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 224 sites in all
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)Pivotal-lookingActive, not recruiting
Currax PharmaceuticalsIndustry
NCT06098079 · 8,600 participants (planned) · Start Jan 3, 2024 · Primary completion Jan 2029
Drug: Naltrexone-Bupropion (NB) Combination; Placebo · For: Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 140 sites in all
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- ISTAPS: A Stepped Primary Care Smoking Cessation InterventionPivotal-lookingStatus unknown
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT00125905 · 3,012 participants · Start Oct 2003
Drug: Nicotine Gum and Patch; Bupropion · For: Smoking Cessation
Sites: Barcelona, Spain
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I TrialPivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04604509 · 2,010 participants (planned) · Start Aug 4, 2020 · Primary completion Dec 31, 2028
Drug: Bupropion Hydrochloride Controlled-release; Nicotine Replacement and 1 more · For: Cigarette Smoking-Related Carcinoma
Sites: Houston, Texas
- A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00532779 · 1,742 participants · Start Oct 2007 · Primary completion May 2009
Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Naltrexone SR 32 mg/Bupropion SR 360 mg /day and 1 more · For: Obesity; Overweight
Sites: Birmingham, Alabama; Fairhope, Alabama; Chandler, Arizona · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,989
- headache1,116
- dizziness1,051
- vomiting680
- constipation648
- feeling abnormal583
- fatigue526
- anxiety406
- insomnia396
- diarrhoea374
- drug ineffective368
- patient dissatisfaction with treatment344
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 13 |
| 2015 | 1,572 |
| 2016 | 832 |
| 2017 | 210 |
| 2018 | 243 |
| 2019 | 308 |
| 2020 | 439 |
| 2021 | 276 |
| 2022 | 355 |
| 2023 | 432 |
| 2024 | 1,327 |
| 2025 | 2,412 |
| 2026 | 84 |
Recalls
2 FDA enforcement reports for this application.
Oct 5, 2018 · Class III · Terminated
Container packaging defect.
Aug 9, 2018 · Class III · Terminated
Defective Container: Customer complaints of punctures in the bottle.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Contrave (Naltrexone HCl/Bupropion HCl)
2024 spending
$1.9M
Beneficiaries
824
2,365 claims
Per beneficiary
$2,315
$4.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $71,732 |
| 2021 | $104,905 |
| 2022 | $447,017 |
| 2023 | $1,583,918 |
| 2024 | $1,907,632 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
Iosifescu DV, Jones A, O'Gorman C, et al. · J Clin Psychiatry 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
Chan B, Kondo K, Freeman M, et al. · J Gen Intern Med 2019 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, et al. · Lancet 2016 · Multicenter Study, Randomized Controlled Trial
- Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
Tabuteau H, Jones A, Anderson A, et al. · Am J Psychiatry 2022 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.